NightHawk Biosciences, Inc., (NHWK): Price and Financial Metrics
NHWK Price/Volume Stats
| Current price | $0.41 | 52-week high | $1.16 |
| Prev. close | $0.38 | 52-week low | $0.26 |
| Day low | $0.37 | Volume | 173,100 |
| Day high | $0.43 | Avg. volume | 97,242 |
| 50-day MA | $0.38 | Dividend yield | N/A |
| 200-day MA | $0.55 | Market Cap | 10.78M |
NHWK Stock Price Chart Interactive Chart >
NHWK Stock Summary
- NHWK has a higher market value than just 5.83% of US stocks; more precisely, its current market capitalization is $10,954,394.
- As for revenue growth, note that NHWK's revenue has grown -67.81% over the past 12 months; that beats the revenue growth of merely 3.08% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NHWK comes in at 25.35% -- higher than that of 93.05% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to NIGHTHAWK BIOSCIENCES INC are FCEL, ADTN, ASXC, NWBO, and OMIC.
- Visit NHWK's SEC page to see the company's official filings. To visit the company's web site, go to www.heatbio.com.
NHWK Valuation Summary
- In comparison to the median Healthcare stock, NHWK's price/sales ratio is 136.36% higher, now standing at 5.2.
- NHWK's price/earnings ratio has moved up 10 over the prior 126 months.
Below are key valuation metrics over time for NHWK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NHWK | 2023-12-29 | 5.2 | 0.3 | -0.2 | -0.4 |
| NHWK | 2023-12-28 | 5.7 | 0.4 | -0.2 | -0.4 |
| NHWK | 2023-12-27 | 5.7 | 0.4 | -0.2 | -0.4 |
| NHWK | 2023-12-26 | 4.3 | 0.3 | -0.2 | -0.4 |
| NHWK | 2023-12-22 | 4.0 | 0.2 | -0.2 | -0.4 |
| NHWK | 2023-12-21 | 3.8 | 0.2 | -0.2 | -0.3 |
NHWK Growth Metrics
- Its 5 year cash and equivalents growth rate is now at 84.6%.
- The 4 year cash and equivalents growth rate now stands at 84.6%.
- Its 3 year cash and equivalents growth rate is now at -18.93%.
The table below shows NHWK's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 6.916352 | -9.248009 | -44.8466 |
| 2022-06-30 | 1.378066 | -28.55552 | -39.27397 |
| 2022-03-31 | 1.786579 | -43.49359 | -35.65988 |
| 2021-12-31 | 2.112806 | -38.12891 | -35.07147 |
| 2021-09-30 | 2.102898 | -33.18167 | -27.95969 |
| 2021-06-30 | 2.451063 | -22.94841 | -29.37858 |
NightHawk Biosciences, Inc., (NHWK) Company Bio
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Latest NHWK News From Around the Web
Below are the latest news stories about NIGHTHAWK BIOSCIENCES INC that investors may wish to consider to help them evaluate NHWK as an investment opportunity.
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research UniversityNext phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as state-of-the-art San Antonio facility helps address industry-wide scarcity for large molecule manufacturing DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announc |
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical CompanyManufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this year; set to expand upon client’s regulatory filing and start of commercial manufacturing DURHAM, N.C., Dec. 18, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announ |
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core AssetsOver $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million in commitments and reduce operating expenses by more than $13 million per year DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) today (“NightHawk” or the “Company”) announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing |
NightHawk Biosciences Provides Q3 2023 Business UpdateDURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are very pleased with the progress of our Scorpius San Antonio facility where operations |
NHWK: 2Q:23 ResultsBy John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported 2Q:23 results in mid-August as presented in a press release and in the filing of its Form 10-Q . Since our previous update in May, it has been quiet; however, Scorpius has continued to generate revenues and is developing its process development activities. In April, the final |
NHWK Price Returns
| 1-mo | -5.31% |
| 3-mo | -2.36% |
| 6-mo | -35.05% |
| 1-year | -62.04% |
| 3-year | -95.10% |
| 5-year | -95.56% |
| YTD | -6.88% |
| 2023 | -45.31% |
| 2022 | -73.52% |
| 2021 | -43.28% |
| 2020 | 61.20% |
| 2019 | -51.53% |
Loading social stream, please wait...